For Investors

EuMentis has completed a Series A to fund development to an IND filing of an NMDA antagonist for ASD, and is conducting a Series B round to fund development of EM-221 through Phase 2.  For more information, please contact Mark Tepper (CEO)

Our unique synthetic approach has many possible applications. We are always looking to capitalize on our team’s talent and experience by acquiring new promising therapies or partnering with like-minded companies or inventors.

Latest news

EuMentis Therapeutics Inc. Announces Closing of Series A Financing

October 27, 2020

Download PDF

EuMentis Therapeutics Inc. Announces Company Launch

February 13, 2020

EuMentis Therapeutics Inc. Announces Company Launch and Focus on Developing Novel Therapeutics to Treat High Value Neurodevelopmental and Neurodegenerative Diseases

Download PDF